Purpose of reviewBroad-based access, uptake, and dissemination of daily oral HIV preexposure prophylaxis (PrEP) have been slow, despite strong evidence for efficacy. Effective and efficient implementation of long-acting HIV prevention products will require both analysis of the dynamics and determinants of daily oral PrEP implementation and identification of the distinct challenges and opportunities inherent in emerging technologies.Recent findingsEvidence suggests the importance of addressing implementation issues at three levels: patient, provider, and system. Patient-level factors include targeted education and messaging, tailored supports to enhance acceptability and uptake, and effective strategies for promoting adherence/persistence and retention in care. Provider-level factors include engaging a broad mix of providers, while ensuring adequate training and support for patient assessment, counseling, and follow-up. Systems-level factors include optimal delivery modalities, resource allocation, and ensuring access to populations most in need of new prevention options.SummaryFormative social/behavioral research must be undertaken proactively to prepare for and address future implementation challenges and reduce the gap between proving efficacy in clinical trials and assuring real-world effectiveness. Conceptualizing new HIV prevention technologies as behavioral interventions at the level of the patient, provider, and system will be paramount to effective and efficient implementation.
机构:
Chelsea & Westminster Hosp, St Stephens Ctr, Dept HIV Genitourinary Med, London, EnglandChelsea & Westminster Hosp, St Stephens Ctr, Dept HIV Genitourinary Med, London, England
Jackson, Akil
McGowan, Ian
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Div Gastroenterol Hepatol Nutr, Pittsburgh, PA USAChelsea & Westminster Hosp, St Stephens Ctr, Dept HIV Genitourinary Med, London, England
机构:
US FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USAUS FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USA
Arya, Vikram
Au, Stanley
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USAUS FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USA
Au, Stanley
Belew, Yodit
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Antiviral Prod, Silver Spring, MD USAUS FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USA
Belew, Yodit
Miele, Peter
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Antiviral Prod, Silver Spring, MD USAUS FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USA
Miele, Peter
Struble, Kimberly
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Antiviral Prod, Silver Spring, MD USAUS FDA, Off Clin Pharmacol, Off Translat Sci, Div Clin Pharmacol 4, Silver Spring, MD USA
机构:
Univ Manchester, Div Psychol & Mental Hlth, Manchester, England
Barwon Hlth, Mental Hlth Drugs & Alcohol Serv MHDAS, Geelong, AustraliaUniv Manchester, Div Psychol & Mental Hlth, Manchester, England
Haddad, Peter M.
Correll, Christoph U.
论文数: 0引用数: 0
h-index: 0
机构:
Northwell Hlth, Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA
Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Psychiat & Mol Med, Hempstead, NY USA
Charite Univ Med Berlin, Dept Child & Adolescent Psychiat, Berlin, GermanyUniv Manchester, Div Psychol & Mental Hlth, Manchester, England